Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions

CNS Drugs

Volumn 23, Issue 9, 2009, Pages 739-753

  Dell'Agnello, Grazia ^a,f   Zuddas, Alessandro ^b   Masi, Gabriele ^c   Curatolo, Paolo ^d   Besana, Dante ^e   Rossi, Andrea ^a  

^a ELI LILLY   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e Hospital of Alessandria   (Italy)

^f Eli Lilly Italia SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; FLUOXETINE; METHYLPHENIDATE; MOOD STABILIZER; PLACEBO;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY DISORDER; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; AUTISM; BILIRUBIN BLOOD LEVEL; BIPOLAR DISORDER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONDUCT DISORDER; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL IRRITATION; GILLES DE LA TOURETTE SYNDROME; HEART RATE; HEPATITIS; HUMAN; JAUNDICE; LIVER INJURY; MAJOR DEPRESSION; MANIA; MORBIDITY; NAUSEA AND VOMITING; NOCTURNAL ENURESIS; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SUICIDE ATTEMPT; SYMPTOM; TIC;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; PROPYLAMINES;

EID: 68949202900     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11314350-000000000-00000     Document Type: Review

References (107)

1. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000 Jul; 9 (3): 481-98
2. Olfson M. Diagnosing mental disorders in office-based pediatric practice. J Dev Behav Pediatr 1992 Oct; 13 (5): 363-5
3. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007 Jun; 164 (6): 942-8
4. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006 Feb; 36 (2): 159-65
5. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006 Feb; 36 (2): 167-79
6. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry 1999; 40: 57-87
7. Kadesjö B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001; 42: 487-92
8. MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: the MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999 Dec; 56 (12): 1073-86
9. Steinhausen H, Metzke C, Meier M, et al. Prevalence of child and adolescent psychiatric disorders: the Zurich Epidemiological Study. Acta Psychiatr Scand 1998; 98: 262-71
10. Steinhausen H-C, Novik T, Baldursson G, et al. Coexisting psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006; 15 Suppl. 1: 25-9
11. Dunn DW, Austin JK, Caffrey HM, et al. A prospective study of teachers' ratings of behaviour problems in children with new-onset seizures. Epilepsy Behav 2003 Feb; 4 (1): 26-35
12. Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol 2005 Jan; 32 (1): 1-10
13. Lewinsohn PM, Rohde P, Seeley JR. Adolescent psychopathology III: the clinical consequences of comorbidity. J Am Acad Child Adolesc Psychiatry 1995; 34: 510-9
14. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40: 147-58
15. March JS, Swanson JM, Arnold LE, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol 2000 Dec; 28 (6): 527-41
16. Consoli A, Bouzamondo A, Guilè JM, et al. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatry 2007 May; 52 (5): 323-8
17. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22 (3): 213-37
18. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behaviour: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114 (1): e1-8
19. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomised prospective study. Adv Ther 2005 Sep-Oct; 22 (5): 498-512
20. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomised, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41 (7): 776-84
21. Michelson D. A double-blind placebo-controlled comparison of atomoxetine, OROS methyphenidate and placebo. American Academy of Child and Adolescent Psychiatry Meeting; 2004 Oct 19-23; Washington, DC
22. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomised, placebo-controlled studies. Biol Psychiatry 2003 Jan 15; 53 (2): 112-20
23. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomised, placebo-controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1896-901
24. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomised, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004 Jul; 43 (7): 896-904
25. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomised, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108 (5): E83
26. Michelson D, Gao H, Allen AJ, et al. Plasma atomoxetine concentration and response to ADHD in children and adolescents. 42nd Annual Meeting of the New Clinical Drug Evaluation Unit; 2002 Jun 10-13; Boca Raton (FL)
27. Sangal R, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006; 29: 1573-85
28. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001 Fall; 11 (3): 251-65
29. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998 May; 155 (5): 693-5
30. Spencer T, Heiligenstein JH, Biederman J, et al.Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-7
31. Weiss M, Tannock R, Kratochvil C, et al. A randomised, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jul; 44 (7): 647-55
32. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005 Aug; 9 (1): 275-89
33. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008 Jun; 165 (6): 721-30
34. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: The Guildford Press, 1998
35. Connors CK. Connors' rating scales: revised technical manual. North Tonawanda (NY): Multi-Health Systems, Inc., 1997
36. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Aug; 45 (8): 919-27
37. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006 Jul; 149 (1): 112-9
38. Turgay A. Atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder. Future Drugs 2006; 3: 19-38
39. Wolraich M, Wibbelsman C, Brown T, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005; 115: 1734-46
40. Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004; 8: 45-52
41. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008; 121 (2): 314-20
42. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
43. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 240-8
44. Kratochvil CS, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005; 44: 915-24
45. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119-27
46. Sumner C, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety [abstract]. Int J Neuropsychopharmacol 2006; 9 Suppl. 1: 135
47. Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/ hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007 Aug; 17 (4): 407-20
48. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec; 65: 1941-9
49. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006 Oct; 45: 1196-205
50. August GJ, Realmuto GM, MacDonald 3rd AW, et al. Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behaviour. J Abnorm Child Psychol 1996 Oct; 24 (5): 571-95
51. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991 May; 148 (5): 564-77
52. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998 Apr; 279 (14): 1100-7
53. Greene RW, Biederman J, Zerwas S, et al. Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder. Am J Psychiatry 2002 Jul; 159 (7): 1214-24
54. Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997 Dec; 36 (12): 1715-25
55. Biederman J, Spencer T, Newcorn J, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007; 190: 31-41
56. Dunne JE. Attention-deficit/hyperactivity disorder and associated childhood disorders. Prim Care 1999 Jun; 26 (2): 349-72
57. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
58. Curatolo P, Mancini F, Dell'Agnello G, The LYCY Study Group. Quality of life of pediatric patients with attention-deficit/hyperactivity disorder and oppositive defiant disorder: an Italian double-blind, placebo-controlled study with atomoxetine. The 13th International Congress of the European Society for Child and Adolescent Psychiatry; 2007 Aug 25-29; Florence
59. Hazell P, Zhang S, Wolañczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006; 15: 105-10
60. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 168-79
61. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998; 59 Suppl. 7: 50-8
62. Kunwar A, Dewan M, Faraone SV. Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2007 Apr; 8 (5): 555-62
63. Heiligenstein J, Spencer T, Faries DE, et al. Efficacy of atomoxetine vs placebo in pediatric outpatients with ADHD. Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC: AACAP, 2000
64. Poznanski EO, Mokros HB. Children's Depression Rating Scale (CDRS-R) revised. Los Angeles (CA): Western Psychological Services, 1999
65. Keen D. ADHD and the paediatrician: a guide to management. Curr Paediatr 2005; 15: 133-42
66. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): U.S. Department of Health, Education, and Welfare, 1976. Publication ADM 76-338
67. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989 Jul; 28 (4): 566-73
68. Cohen DJ, Leckman JF, Shaywitz BA. The Tourette's syndrome and other tics. In: Shaffer D, Erhardt AA, Greenhill L, editors. Diagnosis and treatment in pediatric psychiatry. New York: MacMillan Free Press, 1984
69. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008 Jan; 11 (4): 470-81
70. Sturm H, Fernell E, Gillberg C. Autism spectrum disorders in children with normal intellectual levels: associated impairments and subgroups. Dev Med Child Neurol 2004 Jul; 46 (7): 444-7
71. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behaviour rating scale for the assessment of treatment effects. Am J Ment Defic 1985 Mar; 89 (5): 485-91
72. Troost P, Steinhuis M-P, Tuynman-Qua H, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006 Oct; 16: 611-9
73. Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006 Oct; 16 (5): 599-610
74. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005 Apr; 15 (2): 325-30
75. Faraone SV, Biederman J, Wozniak J, et al. Is comorbidity with ADHD a marker for juvenile-onset mania? J Am Acad Child Adolesc Psychiatry 1997 Aug; 36 (8): 1046-55
76. Findling RL, Gracious BL, McNamara NK, et al. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord 2001 Aug; 3 (4): 202-10
77. Kafantaris V, Coletti DJ, Dicker R, et al. Are childhood psychiatric histories of bipolar adolescents associated with family history, psychosis, and response to lithium treatment? J Affect Disord 1998 Nov; 51 (2): 153-64
78. Kutcher S, Robertson HA, Bird D. Premorbid functioning in adolescent onset bipolar I disorder: a preliminary report from an ongoing study. J Affect Disord 1998 Nov; 51 (2): 137-44
79. Masi G, Perugi G, Toni C, et al. Attention-deficit hyperactivity disorder: bipolar comorbidity in children and adolescents. Bipolar Disord 2006 Aug; 8 (4): 373-81
80. West SA, McElroy SL, Strakowski SM, et al. Attention deficit hyperactivity disorder in adolescent mania. Am J Psychiatry 1995 Feb; 152 (2): 271-3
81. Geller B, Zimerman B, Williams M, et al. DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Child Adolesc Psychopharmacol 2002 Spring; 12 (1): 11-25
82. Jaworowski S, Benarroch F, Gross-Tsur V. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. J Child Adolesc Psychopharmacol 2006; 16: 365-70
83. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005; 15: 996-1004
84. Pliszka SR, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Am Acad Child Adolesc Psychiatry 2007 Jul; 46 (7): 894-921
85. Eli Lilly and Company Limited. Strattera: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinterFriendly.asp?documentid=14482 [Accessed 2008 Dec 17]
86. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006 Jul; 10 (23): iii-iv, xiii-146
87. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26 (10): 729-40
88. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50-5
89. Eli Lilly and Company Limited. Strattera (atomoxetine hydrochloride) capsules for oral use. Prescribing information [online]. Available from URL: http://pi.lilly.com/us/strattera-pi.pdf [Accessed 2008 Dec 17]
90. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31 (4): 345-54
91. Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006 Jun; 148 (6): 831-4
92. Stojanovski SD, Casavant MJ, Mousa HM, et al. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 2007; 45 (1): 51-5
93. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behaviour events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 209-18
94. Lee TS, Lee TD, Lombroso PJ, et al. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 2004 Sep; 43 (9): 1068-9
95. Párraga HC, Párraga KL, Harris DK, et al. Abdominal tics during atomoxetine treatment in a child with ADHD: evaluation and differential diagnosis [letter]. CNS Spectr 2008 Sep; 13 (9): E1
96. Párraga HC, Párraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med 2007; 37 (4): 415-24
97. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [letter]. Am J Psychiatry 2004 Apr; 161 (4): 757
98. Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother 2005 Jun; 39 (6): 1045-8
99. Wernicke JF, Holdridge KC, Jin L, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007 Jul; 49 (7): 498-502
100. Wernicke JF, Chilcott K, McAfee A, et al. Seizure risk in patients with ADHD treated with atomoxetine. Annual Meeting of the American Academy of Children and Adolescent Psychiatry; 2005 Oct 18-23; Toronto (ON)
101. Dunn DW, Austin JK, Harezlak J, et al. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003 Jan; 45 (1): 50-4
102. Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004 Jul; 61 (7): 731-6
103. Double blind, placebo controlled, crossover study of extended release methylphenidate for treatment of ADHD in children with epilepsy [ClinicalTrials.gov identifier NCT00323947]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Jan 30]
104. Barton J. Atomoxetine: a new pharmacotherapeutic approach in themanagement of attention deficit/hyperactivity disorder. Arch Dis Child 2005 Feb; 90 Suppl. 1: i26-9
105. Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care 2004 Jul; 10 (4 Suppl.): S117-24
106. Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attentiondeficit hyperactivity disorder: clinical approaches and review of current available evidence. Pediatr Drugs 2008; 10 (1): 39-47
107. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. Clinical guideline 72 [online]. Available from URL: http://www.nice.org.uk/CG72 [Accessed 2008 Dec 17]